U.S. Banks Stock News

NYSE:NBR
NYSE:NBREnergy Services

Is Nabors Industries (NBR) Still Attractively Priced After Its 90% One Year Rally

If you are wondering whether Nabors Industries is still attractively priced after a strong run, the key question is how its current share price compares with its underlying value. The stock last closed at US$78.73, with returns of 0.8% over the past week, 14.7% over the past month, 42.1% year to date, and 90.5% over the past year. The 3-year and 5-year returns are declines of 41.0% and 39.4% respectively. These mixed returns across different time periods suggest that sentiment toward Nabors...
NYSE:KEYS
NYSE:KEYSElectronic

Keysight Showcases AI Network Push At MWC 2026 As Valuation Stretches

Keysight Technologies is showcasing accelerated AI driven solutions for next generation wireless and satellite networks at Mobile World Congress 2026. The company is highlighting collaborations with Qualcomm, Samsung, MediaTek and Ericsson, along with the integration of Spirent Communications. New AI powered platforms target radio access network optimization, non terrestrial connectivity, autonomous configuration and digital twin based testing. For investors watching NYSE:KEYS, this AI...
NasdaqGS:SATS
NasdaqGS:SATSMedia

EchoStar’s Heavy Loss And Going Concern Warning Reframe Funding Risk

EchoStar (NasdaqGS:SATS) reported a significant net loss in its latest annual results. Auditor KPMG LLP issued a going concern warning, citing substantial doubt about the company’s ability to continue operating. This development introduces new uncertainty for existing and prospective shareholders. EchoStar, trading at $106.24, comes into this news after very large 1 year and 3 year share price gains, with the stock up 277.5% over the past year and up about 7x over three years. Even with...
NYSE:GRND
NYSE:GRNDInteractive Media and Services

Grindr (GRND) Valuation Check As Mixed Momentum And Premium P/E Shape Expectations

Why Grindr is on investors’ radars today Grindr (GRND) has been drawing attention after recent share price moves, with the stock now around $11.61 and performance over the past month, past 3 months and year giving investors fresh numbers to reassess. See our latest analysis for Grindr. Recent trading has been mixed, with a 12.72% 30 day share price return offset by a 13.94% 90 day share price decline and a 23.32% drop in 1 year total shareholder return. As a result, momentum looks uneven...
NasdaqGS:PZZA
NasdaqGS:PZZAHospitality

A Look At Papa John’s (PZZA) Valuation After Recent Share Price Weakness

Why Papa John's International (PZZA) Is Back on Investors' Radar Papa John's International (PZZA) has drawn fresh attention after recent share price weakness, with the stock showing negative returns over the past month and over the past three months. This has prompted investors to reassess its current valuation. See our latest analysis for Papa John's International. That recent weakness sits on top of a much steeper slide, with a 30 day share price return of 10.52% decline, a 90 day share...
NasdaqGS:CVLT
NasdaqGS:CVLTSoftware

Commvault Systems (CVLT) Valuation Check After New Identity Security Integrations With CloudSEK And Okta

Commvault Systems (CVLT) is back in focus after unveiling two identity security moves: integrating CloudSEK’s credential intelligence and extending its Identity Resilience portfolio to support Okta, both aimed at curbing credential theft and speeding recovery. See our latest analysis for Commvault Systems. Despite a series of recent product and partnership announcements around identity resilience and cyber recovery, Commvault Systems’ 30 day share price return of 6.19% sits against a 90 day...
NasdaqGS:NTNX
NasdaqGS:NTNXSoftware

Nutanix AMD AI Deal Puts Focus On Valuation Gap And Growth Potential

Nutanix (NasdaqGS:NTNX) announced a multi year partnership with AMD to co develop open, full stack AI infrastructure platforms. AMD is also making a significant equity investment in Nutanix as part of the collaboration. The agreement includes joint engineering work, coordinated go to market efforts, and integration of AMD CPUs and GPUs into Nutanix offerings. Nutanix, trading at $39.83, is pairing this new AI focused partnership with AMD with an already mixed share price record. The stock...
NYSE:YOU
NYSE:YOUSoftware

Clear Secure Mount Sinai Deal Tests Healthcare Potential And Valuation Upside

Clear Secure has partnered with Mount Sinai Health System to roll out its CLEAR1 digital identity platform across one of New York City's largest health systems. The collaboration focuses on improving digital experiences for patients and staff while helping streamline day to day healthcare operations. The move reflects Clear Secure's push beyond travel use cases into healthcare, applying its identity technology in a large scale clinical setting. For investors watching Clear Secure...
NasdaqGS:FA
NasdaqGS:FAProfessional Services

Assessing First Advantage (FA) Valuation After Barclays Upgrade And Stronger AI And Workday Momentum

First Advantage (FA) is back on investor radars after Barclays upgraded the stock, pointing to stronger upselling, cross selling and new customer wins, as well as a Workday partnership and growing AI capabilities. See our latest analysis for First Advantage. Even with the Barclays upgrade and fresh catalysts like earnings guidance, a new buyback plan and AI partnerships, recent trading has been mixed, with a 7 day share price return of 4.8% but a year to date share price return showing a...
NYSE:S
NYSE:SSoftware

Is It Time To Reassess SentinelOne (S) After A 28% One-Year Share Price Slide?

If you are wondering whether SentinelOne is starting to look like value or still priced for big expectations, you are not alone. The stock most recently closed at US$14.19, with returns of 8.2% over the past week, 4.2% over the last month, a 3.1% decline year to date, and a 28.5% decline over the past year, which will shape how many investors think about its risk and potential. Recent news flow around SentinelOne has focused on its position in cybersecurity and how it fits into broader...
NasdaqGS:FAST
NasdaqGS:FASTTrade Distributors

Is Fastenal (FAST) Pricing In Too Much Growth After Its Strong Multi‑Year Run?

If you are wondering whether Fastenal's current share price lines up with its underlying worth, you are not alone. This article is designed to help you answer exactly that question. Fastenal's shares last closed at US$46.46, with returns of 0.9% over the past week, a 3.8% decline over the past month, 14.9% year to date, 18.6% over 1 year, 94.2% over 3 years and 122.2% over 5 years. This raises a fair question about what you are really paying for today. Recent coverage has focused on...
NasdaqCM:NAGE
NasdaqCM:NAGEPersonal Products

The Bull Case For Niagen Bioscience (NAGE) Could Change Following Record 2025 Results And Injectable Expansion

Niagen Bioscience recently reported its strongest year to date, with 2025 net sales reaching US$129.4 million, net income of US$17.4 million, and management guiding for 2026 net sales to grow a further 10%–15% year-over-year excluding divested analytical reference standards and services revenue. Alongside this financial progress, the company deepened its intellectual property around nicotinamide riboside injectables and broadened into new categories such as at-home injection kits and...
NasdaqGS:QCOM
NasdaqGS:QCOMSemiconductor

Tighter AI Chip Export Controls and New 6G Bets Might Change The Case For Investing In QUALCOMM (QCOM)

In early March 2026, Qualcomm and its peers pushed back against draft U.S. rules on AI chip export controls, while the company also highlighted new AI, robotics, and 6G initiatives and industry partnerships announced around Mobile World Congress in Barcelona. Despite fresh collaborations in private wireless for utilities and new robotics and edge AI platforms, investors are focused on weakening sales projections and tighter export scrutiny that could limit Qualcomm’s future addressable...
NasdaqGS:CERT
NasdaqGS:CERTHealthcare Services

Assessing Certara (CERT) Valuation After FDA PBPK Milestone And Latest Earnings Guidance

Certara (CERT) is back in focus after its physiologically based pharmacokinetic modeling underpinned the U.S. FDA review of asciminib, with simulations accepted in place of several clinical pharmacology studies for the cancer drug’s new drug application. See our latest analysis for Certara. Despite the FDA validation of its PBPK modeling and a recent earnings update, Certara’s share price return has been weak, with a 30 day share price return of 7.23% decline and a 1 year total shareholder...
NYSE:EME
NYSE:EMEConstruction

A Look At EMCOR Group (EME) Valuation After Strong Results And Higher 2026 Guidance

EMCOR Group (EME) is back in focus after reporting fourth quarter and full year 2025 results, with sales and net income above the prior year, along with new 2026 revenue and earnings guidance. See our latest analysis for EMCOR Group. The strong full year results and higher 2026 guidance come after a period of firm momentum, with a 90 day share price return of 13.18% and a 1 year total shareholder return of 88.42%. However, the recent 1 day and 7 day share price declines suggest investors are...
NasdaqGM:BLBD
NasdaqGM:BLBDMachinery

A Look At Blue Bird (BLBD) Valuation After Micro Bird Buyout And Raised Earnings Outlook

Blue Bird’s Micro Bird buyout and earnings momentum come into focus Blue Bird (BLBD) has drawn fresh attention after moving to buy out Girardin’s 50% stake in the Micro Bird joint venture, while recent earnings results and an updated revenue and EBITDA outlook have also been in focus for investors. See our latest analysis for Blue Bird. At a share price of US$54.74, Blue Bird has recently seen a 10.16% 1 month share price return and a 17.07% year to date share price return. Its 1 year total...
NasdaqGS:MRNA
NasdaqGS:MRNABiotechs

Patent Truce on mRNA Delivery Might Change The Case For Investing In Moderna (MRNA)

In early March 2026, Genevant Sciences, Arbutus Biopharma and Moderna reached a global settlement of up to US$2.25 billion over alleged unauthorized use of lipid nanoparticle delivery technology in Moderna’s COVID-19 vaccines, with US$950 million due upfront and the remainder contingent on the outcome of a Section 1498 appeal. The agreement not only ends all related litigation but also grants Moderna a global non-exclusive license for infectious disease applications, clarifying its freedom...
NasdaqGS:ITRN
NasdaqGS:ITRNCommunications

Stronger Results, Richer Dividend, Stellantis Win Could Be A Game Changer For Ituran (ITRN)

Ituran Location and Control recently reported Q4 2025 and full-year 2025 results showing higher revenue and net income year over year, and the board approved a US$1.50 per-share cash dividend totaling about US$30,000,000, payable on April 16, 2026 to shareholders of record on March 30, 2026 at a reduced 20% withholding tax rate. Alongside these results, Ituran was selected to deliver Stellantis’s Connect Fiat program for the Fiat Strada on an initially three-year term, marking a deeper role...
NYSE:LNC
NYSE:LNCInsurance

How Six Straight Quarters of Income Growth Could Shape Lincoln National’s (LNC) Capital Return Path

In early March 2026, Lincoln National reported its sixth consecutive quarter of growth in adjusted operating income, with management highlighting broad-based strength across Group Protection, Annuities, Retirement Plan Services, and Life Insurance on its Q4 2025 earnings call. At the same time, analysts at firms such as Wells Fargo and Morgan Stanley reiterated positive views on the insurer, emphasizing improving free cash flow, lower leverage, and clearer prospects for future capital...
NYSE:WLY
NYSE:WLYMedia

John Wiley & Sons (WLY) Is Up 20.8% After Return To Profitability And New AI Content Deal – Has The Bull Case Changed?

In early March 2026, John Wiley & Sons, Inc. reported fiscal third-quarter sales of US$410.04 million, returning to a net income of US$29.68 million and positive earnings per share from continuing operations after a loss in the same period a year earlier. Separately, OpenEvidence announced a partnership to integrate a wide portfolio of Wiley’s peer-reviewed medical and scientific content into its point-of-care platform, highlighting how Wiley’s research assets are being embedded in...
NYSE:LII
NYSE:LIIBuilding

Lennox Enters Water Heating With Ariston JV As Valuation Stays Steady

Lennox International (NYSE:LII) has entered the North American water heating market through a joint venture with Ariston Group. The partnership is launching a new line of water heaters, adding to Lennox's existing product portfolio. The move expands Lennox's dealer network and allows contractors to offer integrated HVAC and water heating solutions. Lennox International, best known for residential and commercial HVAC systems, is now stepping into water heating, a closely related category...
NYSE:THC
NYSE:THCHealthcare

Has The Surge In Tenet Healthcare (THC) Shares Left Much Upside On The Table?

If you are wondering whether Tenet Healthcare at around US$236.95 is still offering value after a strong run, or if most of the upside is already priced in, this article is here to help you frame that question clearly. The stock has been volatile recently, with a 1% decline over the last 7 days, a 24.3% gain over the last 30 days, an 18.8% return year to date, an 85.9% return over 1 year, and a very large 3 year and 5 year return. This naturally raises questions about risk, sentiment, and...
NasdaqGS:OMDA
NasdaqGS:OMDAHealthcare

Omada Health (OMDA) Is Up 14.4% After GLP-1 Flex Launch and Narrowed 2025 Net Loss

In early March 2026, Omada Health launched its GLP-1 Flex Care program for employer clients and reported fourth-quarter 2025 revenue of US$75.85 million with net income of US$5.16 million, alongside full-year 2025 revenue of US$260.21 million and reduced annual net loss of US$12.78 million. By combining a cash-pay GLP-1 access model that limits employers’ drug spend with improving profitability metrics, Omada is positioning its virtual care platform as both a cost-control and...
NYSE:TPB
NYSE:TPBTobacco

Institutional Split On Turning Point Brands Nicotine Pouch Pivot And Valuation

Large investors have been actively reshaping their positions in Turning Point Brands (NYSE:TPB) following the company’s move toward nicotine pouches. Apis Capital Advisors has raised its stake, while Cannell Capital has cut its holdings, with both changes occurring soon after a strong earnings report. These moves highlight differing views on the shift from legacy products to modern oral nicotine and the role of nicotine pouches in TPB’s future. Turning Point Brands, trading at $91.66, has...